PT - JOURNAL ARTICLE AU - Albert Prats-Uribe AU - Anthony G. Sena AU - Lana Yin Hui Lai AU - Waheed-Ul-Rahman Ahmed AU - Heba Alghoul AU - Osaid Alser AU - Thamir M Alshammari AU - Carlos Areia AU - William Carter AU - Paula Casajust AU - Dalia Dawoud AU - Asieh Golozar AU - Jitendra Jonnagaddala AU - Paras P. Mehta AU - Mengchun Gong AU - Daniel R. Morales AU - Fredrik Nyberg AU - Jose D. Posada AU - Martina Recalde AU - Elena Roel AU - Karishma Shah AU - Nigam H. Shah AU - Lisa M. Schilling AU - Vignesh Subbian AU - David Vizcaya AU - Lin Zhang AU - Ying Zhang AU - Hong Zhu AU - Li Liu AU - Peter Rijnbeek AU - George Hripcsak AU - Jennifer CE Lane AU - Edward Burn AU - Christian Reich AU - Marc A. Suchard AU - Talita Duarte-Salles AU - Kristin Kostka AU - Patrick Ryan AU - Daniel Prieto-Alhambra TI - Heterogeneity and temporal variation in the management of COVID-19: a multinational drug utilization study including 71,921 hospitalized patients from China, South Korea, Spain, and the United States of America AID - 10.1101/2020.09.15.20195545 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.15.20195545 4099 - http://medrxiv.org/content/early/2020/09/19/2020.09.15.20195545.short 4100 - http://medrxiv.org/content/early/2020/09/19/2020.09.15.20195545.full AB - Objectives A plethora of medicines have been repurposed or used as adjunctive therapies for COVID-19. We characterized the utilization of medicines as prescribed in routine practice amongst patients hospitalized for COVID-19 in South Korea, China, Spain, and the USA.Design International network cohortSetting Hospital electronic health records from Columbia University Irving Medical Centre (NYC, USA), Stanford (CA, USA), Tufts (MA, USA), Premier (USA), Optum EHR (USA), department of veterans affairs (USA), NFHCRD (Honghu, China) and HM Hospitals (Spain); and nationwide claims from HIRA (South Korea)Participants patients hospitalized for COVID-19 from January to June 2020Main outcome measures Prescription/dispensation of any medicine on or 30 days after hospital admission dateAnalyses Number and percentage of users overall and over timeResults 71,921 people were included: 304 from China, 2,089 from Spain, 7,599 from South Korea, and 61,929 from the USA. A total of 3,455 medicines were identified. Common repurposed medicines included hydroxychloroquine (<2% in NFHCRD to 85.4% in HM), azithromycin (4.9% in NFHCRD to 56.5% in HM), lopinavir/ritonavir (<3% in all US but 34.9% in HIRA and 56.5% in HM), and umifenovir (0% in all except 78.3% in NFHCRD). Adjunctive medicines were used with great variability, with the ten most used treatments being (in descending order): bemiparin, enoxaparin, heparin, ceftriaxone, aspirin, vitamin D, famotidine, vitamin C, dexamethasone, and metformin. Hydroxychloroquine and azithromycin increased rapidly in use in March-April but declined steeply in May-June.Conclusions Multiple medicines were used in the first months of COVID-19 pandemic, with substantial geographic and temporal variation. Hydroxychloroquine, azithromycin, lopinavir-ritonavir, and umifenovir (in China only) were the most prescribed repurposed medicines. Antithrombotics, antibiotics, H2 receptor antagonists and corticosteroids were often used as adjunctive treatments. Research is needed on the comparative risk and benefit of these treatments in the management of COVID-19.What is already known in this topicWhat is already known in this topicDrug repurposing is a common approach in the clinical management of novel diseases and conditions for which there are no available pharmacotherapiesHydroxychloroquine was widely used in the management of COVID-19 patients during the early phases of the pandemicRecent NIH (and other) guidelines recommend the use of concomitant therapies including immune-based, antithrombotic, antibiotic and other treatmentsWhat this study addsWhat this study addsThis study demonstrates great variability and extensive drug repurposing and utilization in the management of COVID-19 patients.A wide range of adjunctive treatments has been used, including antithrombotics, antibiotics, H2 receptor antagonists, and systemic corticosteroids.Emerging clinical data on the safety and efficacy of hydroxychloroquine and azithromycin impacted their rise and rapid decline in use internationallyConversely, the use of corticosteroids grew only in more recent months, with little use in the early stages of the pandemic (January to April)Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Dr Prieto-Alhambra reports grants and other from AMGEN; grants, non-financial support and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organized by DPA's department and open for external participants. : SCY reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study; AS reports personal fees from Janssen Research & Development, during the conduct of the study; personal fees from Janssen Research & Development, outside the submitted work; KK is an employee of IQVIA; HAb is an employee and shareholder of Eli Lilly and Company; AA is an employee at Alberta Health Services (AHS) and has been redeployed to aid in the COVID-19 response, this work was not conducted at AHS, within AHS working hours, or with AHS staff, but as a member of the Observational Health Data Sciences and Informatics (OHDSI) Network; JC reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study; FJDF reports personal fees from Janssen Research & Development, during the conduct of the study; personal fees from Janssen Research & Development, outside the submitted work; WURA reports funding from the NIHR Oxford Biomedical Research Centre (BRC), Aziz Foundation, Wolfson Foundation, and the Royal College Surgeons of England; SLDV reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Biomedical Research outside the submitted work; WG is an AbbVie employee; AG reports personal fees from Regeneron Pharmaceuticals, and full-time employment at Regeneron Pharmaceuticals, outside the submitted work; JH is a full-time employee of Janssen Research & Development, and a shareholder of Johnson & Johnson; GH reports grants from US NIH National Library of Medicine, during the conduct of the study; grants from Janssen Research, outside the submitted work; HJ reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study; YJ is an AbbVie employee and shareholder; BSKH reports grants from Innovation Fund Denmark (5153-00002B) and the Novo Nordisk Foundation (NNF14CC0001), outside the submitted work; RM is an employee of Janssen Research and Development; DRM reports funding support from the Wellcome Trust, NIHR, Scottish CSO and Tenovus Scotland for research unrelated to this work; RWP reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study; JP reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study; APU reports grants from Fundacion Alfonso Martin Escudero, grants from Medical Research Council, outside the submitted work; GAR is a full time employee of Janssen and shareholder of Johnson & Johnson; CR is an employee of IQVIA; PR reports grants from Innovative Medicines Innitiative, grants from Janssen Research and Development, during the conduct of the study; MS is a full-time employee of Janssen R&D, and a shareholder of Johnson & Johnson; AS is a full time employee of Janssen and shareholder of Johnson & Johnson; MAS reports grants from US National Science Foundation, grants from US National Institutes of Health, grants from IQVIA, personal fees from Janssen Research and Development, during the conduct of the study; JS was a full-time employees of Johnson & Johnson, or a subsidiary, at the time the study was conducted, and owns stock, stock options, and pension rights from the company; DV reports personal fees from Bayer, outside the submitted work, and full-time employment at Bayer; DPA reports grants and other from AMGEN, grants, non-financial support and other from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organized by DPA's department and open for external participants; PR is an employee of Janssen Research and Development and shareholder of Johnson & Johnson; VS reports funding from US National Science Foundation, funding from the Agency for Healthcare Research and Quality through the University of Utah, and funding from the Arizona Board of Regents. FN was an employee of AstraZeneca until 2019, before the conduct of this study, and owns some AstraZeneca shares. LYHL, EB, DD, MTFA, HAl, OA, TMA, CA, JMB, ACC, AD, TDS, TF, VH, CYJ, DK, SK, YK, SK, JL, HL, KEL, MEM, PM, KN, AO, JDP, YR, LMS, NHS, SS, MS, SV, HW, AEW, BBY, LZ, JJ, MR, ER, HZ, MG and OZ have nothing to report. No other relationships or activities that could appear to have influenced the submitted work.Funding StatementThe European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Unions Horizon 2020 research and innovation programme and EFPIA. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA. This work was also supported by the Bio Industrial Strategic Technology Development Program (20001234) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]. This study was supported by National Key Research & Development Program of China (Project No. 2018YFC0116901). Personal funding included Versus Arthritis [21605], Medical Research Council Doctoral Training Partnership (MRC-DTP) [MR/K501256/1] (JL); MRC-DTP [MR/K501256/1, MR/N013468/1] and Fundacion Alfonso Martin Escudero (FAME) (APU); Innovation Fund Denmark (5153-00002B) and the Novo Nordisk Foundation (NNF14CC0001) (BSKH); VINCI [VA HSR RES 13-457] (SLD, MEM, KEL); and NIHR Senior Research Fellowship (SRF-2018-11-ST2-004, DPA). The University of Oxford received funding related to this work from the Bill & Melinda Gates Foundation (Investment ID INV-016201 and INV-019257). No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, Department of Veterans Affairs or the United States Government, the Ministry of Science and Technology of China, NHS or the Department of Health, EnglandAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All the data partners received Institutional Review Board (IRB) approval or exemption. STARR-OMOP had approval from IRB Panel #8 (RB-53248) registered to Leland Stanford Junior University under the Stanford Human Research Protection Program (HRPP). The use of VA data was reviewed by the Department of Veterans Affairs Central Institutional Review Board (IRB) and was determined to meet the criteria for exemption under Exemption Category 4(3) and approved the request for Waiver of HIPAA Authorization. The research was approved by the Columbia University Institutional Review Board as an OHDSI network study. The IRB number for use of HIRA data was AJIB-MED-EXP-20-065). The use of HM Hospitals was approved by the Clinical Research Ethics Committee of the IDIAPJGol (project code: 20/070-PCV). The collection and usage of the data for clinical research in NFHCRD was approved by the IRB of Nanfang Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalyses were performed locally, and the data is not readily available to be shared. However, all analytic code is available at: https://github.com/ohdsi-studies/Covid19CharacterizationCharybdis and results are available at https://data.ohdsi.org/Covid19CharacterizationCharybdis/ https://data.ohdsi.org/Covid19CharacterizationCharybdis/ https://github.com/ohdsi-studies/Covid19CharacterizationCharybdis